Next Article in Journal
Ivermectin Attenuates CCl4-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation
Next Article in Special Issue
Optic Nerve Structural and Functional Changes in LHON-Affected and Asymptomatic Maternal Relatives: Association with H and HV Mitochondrial Haplogroups
Previous Article in Journal
Anion-Controlled Synthesis of Novel Guanidine-Substituted Oxanorbornanes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 24
10.3390/ijms232416038
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Latest Evidence of Erythropoietin in the Treatment of Glaucoma

Int. J. Mol. Sci. 2022, 23(24), 16038; https://doi.org/10.3390/ijms232416038
by Ting-Yi Lin, Yi-Fen Lai, Yi-Hao Chen and Da-Wen Lu *
Reviewer 1: Anonymous
Reviewer 2:
Kaori Ueda
Reviewer 3: Anonymous
Int. J. Mol. Sci. 2022, 23(24), 16038; https://doi.org/10.3390/ijms232416038
Submission received: 25 October 2022 / Revised: 6 December 2022 / Accepted: 14 December 2022 / Published: 16 December 2022
(This article belongs to the Special Issue Optic Neuropathies: From Molecular Mechanism to Therapy)

Round 1

Reviewer 1 Report

I would like to apologize with editor and authors for the delay in my response. I have had problem with the mdpi account that was linked to my previous institutional email address (that is now not functional). I hope that the problem is now solved.

The authors collected and discussed an extensive amount of information about the use of erythropoietin in the treatment of glaucoma. the review is clear and well organized in paragraphs. The table is also very clear and exhaustive.

Here some minor suggestions:

- the paragraph in lines 66-80 is not clearly linked to the EPO expression mechanism, please clarify explicitly. A figure with a schematic representation of the EPO expression and/or EPOR activity could help

- the paragraph in lines 257-263 should be moved in the discussion (now is the paragraph related to Microbeads induced glaucoma model

- some moderate english corrections are needed (e.g. line 39 " to BE expressed", line 73 "The hydroxylated HIF-α IS subsequently ubiquitylated by von Hippel-Lindau tumor suppressor"

- clarify some acronyms (e.g. line 45 Hb; line 153 PLGA and PPS)

- clairfy the role of p300 (line 80)

-clarify the informations derived from TUNEL (line 193) 

- references in lines 280 and 326 are of different size

 

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors provide an interesting and clear summary of the role of EPO as it relates to glaucoma. In particular, the summary of table 1 is very attractive, detailed and easy to understand for the non-specialist.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 3 Report

Lu et al present a comprehensive review of the literature regarding EPO and glaucoma, mainly focused on animal models. I usually have comments and suggestions to offer, but it appears that the work is fine in its present form.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop